Fluidigm Corporation (NASDAQ:FLDM) will be posting its quarterly earnings results after the market closes on Thursday, November 2nd. Analysts expect Fluidigm Corporation to post earnings of ($0.31) per share for the quarter.
Fluidigm Corporation (NASDAQ:FLDM) last posted its quarterly earnings data on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.02. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. The business had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $23.50 million. During the same quarter in the prior year, the business posted ($0.63) earnings per share. Fluidigm Corporation’s revenue was down 15.2% compared to the same quarter last year. On average, analysts expect Fluidigm Corporation to post $-1.34 EPS for the current fiscal year and $-0.72 EPS for the next fiscal year.
Shares of Fluidigm Corporation (NASDAQ FLDM) opened at 5.80 on Wednesday. Fluidigm Corporation has a 52-week low of $2.52 and a 52-week high of $8.69. The company’s 50-day moving average is $5.11 and its 200 day moving average is $4.53. The company’s market cap is $170.60 million.
In other Fluidigm Corporation news, Director Samuel D. Colella purchased 35,895 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was purchased at an average price of $2.77 per share, for a total transaction of $99,429.15. Following the transaction, the director now owns 45,197 shares in the company, valued at approximately $125,195.69. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Stephen Christopher Linthwaite purchased 45,000 shares of the company’s stock in a transaction dated Tuesday, August 8th. The shares were acquired at an average price of $2.66 per share, with a total value of $119,700.00. Following the transaction, the chief executive officer now owns 106,977 shares in the company, valued at approximately $284,558.82. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 4,542,671 shares of company stock valued at $15,558,699. 4.70% of the stock is owned by corporate insiders.
An institutional investor recently raised its position in Fluidigm Corporation stock. State Street Corp grew its holdings in shares of Fluidigm Corporation (NASDAQ:FLDM) by 6.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 499,524 shares of the medical research company’s stock after acquiring an additional 29,110 shares during the quarter. State Street Corp owned about 1.70% of Fluidigm Corporation worth $2,017,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 88.61% of the company’s stock.
Separately, ValuEngine upgraded Fluidigm Corporation from a “strong sell” rating to a “sell” rating in a research note on Monday, October 23rd.
Fluidigm Corporation Company Profile
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
What are top analysts saying about Fluidigm Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fluidigm Corporation and related companies.